![Kin Yip Leung](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kin Yip Leung
Directeur/Membre du Conseil chez
NOVOCURE LIMITED
Fortune : 2 M $ au 31/05/2026
Profil
Kin Yip Leung is Vice Chairman at NovoCure Ltd. since 2011.
Former roles include Independent Director at Curia Global, Inc. from 2010 to 2016, Director at Delcath Systems, Inc. in 2014, Director at NanoMed Pharmaceuticals, Inc., Independent Non-Executive Director at Pernix Therapeutics Holdings, Inc. from 2016 to 2019, Principal at Bristol Myers Squibb Co. from 1990 to 1999, EVP and President of Oncology & Diabetes Business at OSI Pharmaceuticals, Inc. from 2003 to 2010, Group Vice President of Global Prescription Business at Pharmacia Corp.
from 1999 to 2003, and Member at C-Change.
Education includes undergraduate studies at The University of Texas at Austin and graduate studies at the University of Wisconsin.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
NOVOCURE LTD. 0,09 % | 03/06/2026 | 101 109 ( 0,09 % ) | 2 M $ | 31/05/2026 |
Postes actifs de Kin Yip Leung
| Sociétés | Poste | Début |
|---|---|---|
| NOVOCURE LIMITED | Directeur/Membre du Conseil | 05/08/2011 |
Anciens postes connus de Kin Yip Leung
| Sociétés | Poste | Fin |
|---|---|---|
| PERNIX THERAPEUTICS HOLDINGS INC | Directeur/Membre du Conseil | 09/05/2019 |
| ALBANY MOLECULAR RESEARCH, INC. | Directeur/Membre du Conseil | 04/02/2016 |
| DELCATH SYSTEMS, INC. | Président | 15/09/2014 |
| OSI PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/01/2010 |
Pharmacia Corp.
 Pharmacia Corp. Pharmaceuticals: MajorHealth Technology Researches, manufactures and sells pharmaceuticals | Corporate Officer/Principal | 01/04/2003 |
Formation de Kin Yip Leung
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
78
Relations au 1er degré
11
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 11 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
OSI Pharmaceuticals, Inc.
 OSI Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and develops pharmaceutical drugs | Health Technology |
Curia Global, Inc.
 Curia Global, Inc. BiotechnologyHealth Technology Operates as a global contract research and manufacturing company that provides drug discovery, development & production services | Health Technology |
Delcath Systems, Inc.
 Delcath Systems, Inc. Medical SpecialtiesHealth Technology Develops and manufactures drugs for treatment of cancer | Health Technology |
NanoMed Pharmaceuticals, Inc.
 NanoMed Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Develops therapeutic and diagnostic products | Commercial Services |
Pharmacia Corp.
Pharmacia Corp. Pharmaceuticals: MajorHealth Technology Researches, manufactures and sells pharmaceuticals | Health Technology |
The University of Texas at Austin
 The University of Texas at Austin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Wisconsin
 University of Wisconsin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
C-Change
 C-Change Other Consumer ServicesConsumer Services C-Change is a private company based in Washington, DC. C-Change was founded by Kevin Sharps, Lynn L. Davison. | Consumer Services |
NovoCure Ltd.
 NovoCure Ltd. Medical SpecialtiesHealth Technology Operates as a commercial-stage oncology company | Health Technology |
Pernix Therapeutics Holdings, Inc.
 Pernix Therapeutics Holdings, Inc. Pharmaceuticals: MajorHealth Technology Develops and distributes pharmaceutical products | Health Technology |
